This phase II trial tests how well Cytalux, registered trademark, (pafolacianine) detects tumor cells using near-infrared (NIR) fluorescent imaging during surgery (intraoperative) in patients undergoing surgery for digestive system, genitourinary system or female reproductive system cancer. Pafolacianine is a fluorescent imaging agent that targets folate receptors (FR) which are overexpressed in many tumors and is used with NIR imaging during surgery to identify tumor cells. NIR imaging uses a special camera that uses wavelengths in the infrared range to visualize and locate the tumor cells that are lit up by the pafolacianine. Intraoperative pafolacianine with NIR imaging may improve tumor cell detection for removal in patients undergoing surgery for digestive system, genitourinary system or female reproductive system cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT07039526.
Locations matching your search criteria
United States
Texas
Dallas
UT Southwestern/Simmons Cancer Center-DallasStatus: Active
Contact: John Waters
Phone: 214-645-7700
PRIMARY OBJECTIVE:
I. To assess the ability of Cytalux™ (pafolacianine sodium [pafolacianine]) injection used with near-infrared (NIR) fluorescent imaging to improve the detection of malignant tissue in subjects undergoing surgical resection for cancer.
SECONDARY OBJECTIVE:
I. To compare the sensitivity and specificity for Cytalux™ used with NIR light with respect to the detection of primary and metastatic cancer in immunohistochemically FR+ tissue.
EXPLORATORY OBJECTIVES:
I. To assess clinical margin, NIR margin, and pathologic margin (where applicable).
II. To evaluate the proportion of subjects whose surgical procedure changed in scope from the planned surgery based on the use of Cytalux™ with NIR imaging.
OUTLINE:
Patients receive pafolacianine intravenously (IV) over 60 minutes 1-24 hours before undergoing normal light visualization and/or palpation followed by NIR fluorescent imaging during standard of care surgery.
After completion of study intervention, patients are followed up at 7-28 days.
Lead OrganizationUT Southwestern/Simmons Cancer Center-Dallas
Principal InvestigatorJohn Waters